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We read with interest the analysis by Reulbach and
colleagues regarding the treatment of neuroleptic malignant
syndrome (NMS) [1]. In this analysis, the effect of various
treatments on clinical outcomes from 271 single case reports
was reviewed. It was concluded that dantrolene does not
seem to be the evidence-based treatment of choice for NMS.
We have concerns about the methodology employed by the
authors, in particular the type of studies included in this
analysis. Guidelines for grading the quality of evidence and
strength of recommendations for the efficacy of an
intervention were recently published, in which the analysis of
single case reports is not a recognized approach for
evaluating a treatment’s efficacy [2]. Furthermore, case series
were specifically excluded by Reulbach and colleagues, even
though these studies can demonstrate the spectrum of
severity and response to treatment, which is more informative.
Other shortcomings in the methodology were also observed,
and although some were acknowledged by the authors,
clinical recommendations were still made.
We acknowledge the difficulties in the treatment of NMS
given that the available data are restricted to case reports
and small case series and agree that large prospective
studies are probably impracticable. However, only limited
conclusions can be drawn from any analyses of these data
even if ‘meta-analysis techniques’ are used. This paper is
valuable for hypothesis generation and we hope that it will
stimulate further discussion. However, recommendations that
influence the use of selected agents in the clinical
management of NMS are not appropriate on the basis of the
present study.
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NMS = neuroleptic malignant syndrome.
Authors’ response
Udo Reulbach, Carmen Dütsch, Teresa Biermann, Wolfgang Sperling, Johannes Kornhuber and Stefan Bleich
We are inclined to agree with Roberts and Roberts
concerning the difficulty in the assessment of the treatment of
NMS.
We discussed the inclusion of case series. On the one hand,
information was lost by the exclusion of those studies. On the
other hand, this was the sole way to avoid biases resulting
from multiple recorded case reports. In our opinion, this
disadvantage outweighs the advantage. Unfortunately,
publication bias is an inescapable feature of reviews or meta-
analysis.
As a matter of course, the evidence level of such analyses is
dependent on the quality of the studies analysed. As the data
are restricted to case reports, it is not feasible to draw
definite recommendations.
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Regarding the main objection by Roberts and Roberts, we
did not recommend specific selected agents. In the past,
dantrolene has been considered the treatment of choice. This
recommendation, which was based on case reports or case
series, could not be confirmed by our analysis, at least in part.
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